BRISTOL MYERS SQUIBB CO (BMY)
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
📈 **POSITIVE** • High confidence analysis (87%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business